• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

eXoZymes Inc. - Common Stock (NQ:EXOZ)

5.770 +0.010 (+0.17%)
Delayed Quote Updated: 3:27 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,117
Open 5.870
Bid (Size) 5.500 (100)
Ask (Size) 7.930 (1,100)
Prev. Close 5.760
Today's Range 5.762 - 6.000
52wk Range 4.350 - 18.40
Shares Outstanding 8,387,250
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Water Tower Research Publishes Initiation of Coverage Report on eXoZymes, Inc., "Converting Cell-Free Science into a Scalable and Repeatable Commercial Opportunity"
October 02, 2026
October 2, 2026, ST. PETERSBURG, FL – Water Tower Research (www.watertowerresearch.com) has published an Initiation of Coverage Report on eXoZymes, Inc. (NASDAQ: EXOZ) titled, “Converting Cell-Free... 
Via TheNewswire.com
Topics Initial Public Offering
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
September 09, 2026
Gainers EXoZymes (NASDAQ:EXOZ) stock increased by 7.5% to $7.18 during Wednesday's after-market session. The market value of their outstanding shares is at $58.5 million. AEON Biopharma (AMEX:AEON)... 
Via Benzinga

Performance

52-Week Range 68.6% below 52-week high
5.770
4.3552W Low 18.4052W High
1 Week 11.6% below 1-week high
5.761W Low 6.531W High

eXoZymes Inc. - Common Stock (EXOZ) traded between $4.35 and $18.40 over the past 52 weeks and last traded at $5.77, 68.6% below its 52-week high. Over the past week it ranged between $5.76 and $6.53.

Past 12 Months
-3.8%
-15.1%
-29.1%
-42.6%
-47.5%
-56.6%
1W -$0.23
1M -$1.03
3M -$2.37
6M -$4.28
YTD -$5.22
1Y -$7.53

EXOZ was -56.6% over the past year, -42.6% over six months, -47.5% year to date, -3.8% in the last week.

12 Months vs Market
EXOZ
-56.6%
DIA
+9.3%
SPY
+15.0%
QQQ
+24.3%
IWM
+14.5%

Over the past 12 months EXOZ returned -56.6% versus DIA (Dow) +9.3%, SPY (S&P 500) +15.0%, QQQ (Nasdaq 100) +24.3% and IWM (Russell 2000) +14.5%.

Volume & Liquidity 0.29× 3-mo avg
Today 2,117 3-mo avg 7.3K
1W
3.1K
1M
7.8K
3M
7.3K
6M
7.6K
YTD
6.2K
1Y
5.5K

EXOZ most recently traded 2,117 shares against a 3-month average daily volume of 7.3K.

More News

Read More
News headline image
eXoZymes Selects Curia as Commercial-Scale Manufacturing Partner for NCT
September 08, 2026
From eXoZymes
Via ACCESS Newswire
News headline image
Investor Summit | MicroCap Opportunities to Watch - August 26
August 24, 2026
From Investor Summit Group
Via ACCESS Newswire
News headline image
eXoZymes Provides Fourth Quarter and Full Year 2025 Update
March 31, 2026
Via ACCESS Newswire
News headline image
Earnings Scheduled For November 13, 2025 ↗
November 13, 2025
Via Benzinga
News headline image
eXoZymes Q2 Earnings Call Highlights ↗
August 20, 2026
Via MarketBeat
Topics Earnings
News headline image
eXoZymes Reports Second Quarter 2026 Results and Provides Business Update at 5PM ET Today
August 20, 2026
From eXoZymes
Via ACCESS Newswire
News headline image
eXoZymes' NCT Process Achieves 10-fold Productivity Increase, Advancing Beyond Original Commercial-scale Economic Targets
August 18, 2026
From eXoZymes
Via ACCESS Newswire
News headline image
eXoZymes to Host Second Quarter 2026 Update Conference Call on Thursday, August 20, 2026
August 11, 2026
From eXoZymes
Via ACCESS Newswire
News headline image
eXoZymes Selected for DoE's Genesis Mission to Advance AI-Powered Digital Twins for Cell-Free Biomanufacturing
July 23, 2026
From eXoZymes
Via ACCESS Newswire
News headline image
Q2 Virtual Investor Summit Presentations Now Available On Demand
June 30, 2026
From Investor Summit Group
Via ACCESS Newswire
News headline image
eXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery
June 24, 2026
From eXoZymes
Via ACCESS Newswire
News headline image
eXoZymes Inc. Announces Closing of $6 Million Public Offering
June 17, 2026
From eXoZymes
Via ACCESS Newswire
News headline image
eXoZymes Inc. Announces Pricing of Public Offering of Common Stock and Warrants
June 08, 2026
Via ACCESS Newswire
News headline image
eXoZymes Announces Graduation from Shell GameChanger(TM) Accelerator Powered by NLR (GCxN) Program
May 07, 2026
Via ACCESS Newswire
News headline image
eXoZymes CCO, Damien Perriman, Outlines NCTx Strategy and the Commercial Path for Cell-Free Biomanufacturing on Grow Everything Podcast
April 10, 2026
Via ACCESS Newswire
News headline image
eXoZymes to Host Fourth Quarter and Full Year 2025 Results Conference Call on Tuesday March 31, 2026
March 25, 2026
Via ACCESS Newswire
News headline image
Successful Pilot Scale Run with Cayman Chemical Validates eXoZymes' Technology and Scalability
March 18, 2026
Via ACCESS Newswire
News headline image
eXoZymes' CCO Damien Perriman to Present a NCT Solution at Next Week's MISTA Symposium
March 12, 2026
Via ACCESS Newswire
News headline image
With Refreshed Brand eXoZymes Sharpens Pharmaceutical Focus to Drive Platform Leverage and Long-Term Value Creation
February 10, 2026
Via ACCESS Newswire
News headline image
eXoZymes Advancing Commercial Readiness With Profound Production Metrics on Initial NCT Pilot Run
January 29, 2026
Via ACCESS Newswire
News headline image
eXoZymes Achieves 100× Scale-up of NCT Production Using Exozymes, Demonstrating Near-perfect Feedstock Conversion
December 11, 2025
Via ACCESS Newswire
News headline image
eXoZymes Provides Third Quarter 2025 Update at 5PM EST Today
November 13, 2025
Via ACCESS Newswire
News headline image
eXoZymes Announces Cell-Free Biomanufacturing Pioneer, Tyler Korman, As CSO & Amy Lunzer as Chief of Staff
November 13, 2025
Via ACCESS Newswire

Frequently Asked Questions

Is eXoZymes Inc. - Common Stock publicly traded?
Yes, eXoZymes Inc. - Common Stock is publicly traded.
What exchange does eXoZymes Inc. - Common Stock trade on?
eXoZymes Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for eXoZymes Inc. - Common Stock?
The ticker symbol for eXoZymes Inc. - Common Stock is EXOZ on the Nasdaq Stock Market
What is the current price of eXoZymes Inc. - Common Stock?
The current price of eXoZymes Inc. - Common Stock is 5.770
When was eXoZymes Inc. - Common Stock last traded?
The last trade of eXoZymes Inc. - Common Stock was at 10/02/26 03:27 PM ET
What is the market capitalization of eXoZymes Inc. - Common Stock?
The market capitalization of eXoZymes Inc. - Common Stock is 48.39M
How many shares of eXoZymes Inc. - Common Stock are outstanding?
eXoZymes Inc. - Common Stock has 48M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap